Objective: To investigate the potential of 8-iso-prostaglandin F 2a ) as a biomarker for disease activity and oxidative stress in the CSF of patients with multiple sclerosis (MS).
Multiple sclerosis (MS) is a disease of unknown cause with multiple factors implicated in its pathophysiology. [1] [2] [3] There is growing evidence of the involvement of oxidative stress in neural damage in MS. [3] [4] [5] [6] Because of the high lipid content in neural tissue, oxidative stress, with its associated increased free radical production, leads to lipid peroxidation. 7 At present there is no established biomarker for investigating lipid peroxidation and oxidative stress in MS.
Isoprostanes are a class of lipid peroxidation products that are generated when free radicals attack the arachidonic acid esterified in phospholipid pools of cell membranes. [7] [8] [9] [10] [11] 8-Iso-prostaglandin F 2a ) is one of the most abundant and well-recognized isoprostanes and is now recognized as a "gold-standard biomarker for in vivo oxidative stress and lipid peroxidation." [10] [11] [12] [13] Oxidative stress may contribute to the disease mechanisms in both the relapsing-remitting and progressive phases of MS through its involvement in inflammation and axonal degeneration, respectively. Increased lipid peroxidation in MS leads to an increase in the markers of oxidative stress, but there is also a depletion of the antioxidant reserves as reported in a study of patients with MS. 14 There have also been some reports of evaluation of the relative production of 8-iso-PGF 2a in biological fluids, mostly in serum and urine in patients with MS. [15] [16] [17] [18] [19] [20] However, there have been no studies to determine levels of isoprostanes in the CSF of patients with MS that also investigate the association with other indicators of oxidative stress (including antioxidant levels) and correlate with disease severity or progression.
The present study aims to evaluate 8-iso-PGF 2a concentrations in the CSF of patients with MS as a marker for oxidative stress and to investigate its association with other oxidative stress parameters.
METHODS Standard protocol approvals, registrations, and patient consents. All CSF and plasma samples were obtained with informed consent and institutional review board (IRB) approval from patient volunteers at the International Multiple Sclerosis Management Practice (IMSMP). All 231 patients with MS included in the study had clinically definite MS as assessed by board-certified neurologists at the IMSMP. 21 Patient selection was a passive rather than an active process, meaning that the first 231 patients whose CSF samples were serially collected for analysis at the start of the study were included in the study. Controls included 24 normal healthy volunteers and 16 patients with other neurologic disorders (ONDs). Although the controls were not perfectly age-matched to the MS subgroups, the mean age for each subgroup was within 66 years of the mean age for the control group. All patients with MS were defined as having relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS), and they were further characterized as having active or stable disease. Active disease was defined by the presence of any one of the following criteria in the 6 months preceding CSF sample collection: (1) one or more relapses documented by neurologist examination; (2) change of 0.5 points or greater in Expanded Disability Status Scale (EDSS) score; and (3) change in MRI, specifically a change in the number or size of lesions or the presence of gadoliniumenhancing lesions.
CSF collection. CSF samples were obtained by standard lumbar puncture or via aspiration of the access port of surgically implanted baclofen pumps with informed consent and IRB approval. CSF was collected from a total of 74 patients with RRMS, 67 patients with PPMS, 90 patients with SPMS, and 40 controls (table). The controls consisted of 24 normal healthy controls and 16 patients with ONDs as follows: 6 patients with CNS inflammatory diseases, 3 with spinal cord injury, 2 with transverse myelitis, 2 with spinal stenosis, and 1 patient each with human T lymphotropic virus type I-associated myelopathy, sarcoidosis, and stiff person syndrome. Serum samples were also collected from 39 patients with MS as a subset for comparison.
CSF was examined to ensure absence of red blood cell contamination and centrifuged at 200g for 15 minutes to remove the cells. Aliquots of CSF were analyzed immediately or stored at 280°C until use.
All the CSF analysis was carried out by researchers blinded to the disease status of the patient.
8-iso-PGF 2a assay by ELISA. 8-iso-PGF 2a levels in the CSF samples were determined using a specific competitive EIA kit from Cayman Chemical (Ann Arbor, MI) as per the vendor's instructions. Briefly, 50 mL of each sample was assayed in duplicate and each assay was repeated at least twice. We also analyzed the respective serum samples of 39 patients with MS for comparison of 8-iso-PGF 2a levels between the serum and CSF.
Thiobarbituric acid reactive substances assay. Lipid peroxidation in the CSF samples was also measured using the thiobarbituric acid reactive substances (TBARS) assay from Cayman Chemical, which measures the formation of malondialdehyde (MDA) from the decomposition of the unstable peroxides derived from polyunsaturated fatty acids. For this assay CSF was concentrated 4 times by overnight lyophilization. Samples were reconstituted in ultrapure water. MDA was assayed in 100 mL of each CSF sample by a fluorescence assay as per the manufacturer's protocol.
Oxidized glutathione. Oxidized glutathione (GSSG) was monitored in the 4 times concentrated CSF samples using a fluorescent assay from BioVision, Inc. (Milpitas, CA).
Superoxide dismutase. Superoxide dismutase (SOD) levels in the CSF samples were analyzed using the colorimetric assay from Cayman Chemical in 10 mL of undiluted CSF samples in duplicate wells. Each assay was repeated at least twice.
Total antioxidant status. The combined nonenzymatic antioxidant capacity-total antioxidant status [TAS]-of CSF samples (concentrated 4 times) was determined using the TAS assay kit from Abcam (Cambridge, UK) using Trilox as a standard as per the manufacturer's protocol.
Experimental allergic encephalitis induction. All animal experiments were approved by the St. Luke's Roosevelt Hospital Center Institutional Animal Care and Use Committee. Experimental allergic encephalitis (EAE) was induced in six 8-week-old female wild-type C57BL/6 mice using MOG35-55 peptide as described previously. 22, 23 Mice were weighed and evaluated for neurologic disability daily by a blinded scorer. Disability was scored using a 0-13 EAE scale as previously described. 23, 24 Mice were sacrificed at disease peak, i.e., on day 15, and total brain lysates were analyzed for 8-iso-PGF 2a levels. Data analysis is representative of 3 individual experiments. with MS, with several patients with RRMS, SPMS, and PPMS having levels greater than 20 pg/mL, a level not exceeded by any control (figure 1A). As a group, patients with progressive disease had higher values than those with RRMS, and only patients with SPMS had values greater than 100 pg/mL. This difference, however, is compounded by the inherent differences between the 2 groups in terms of age, disease duration and severity (table) , and diseasemodifying therapies.
To determine whether the elevated levels in patients with SPMS correlated with disease activity, we analyzed CSF levels of 8-iso-PGF 2a and found a strong correlation with active disease, as depicted in figure 1B (n 5 41 and p , 0.0001) .
The increase in CSF levels of 8-iso-PGF 2a appeared to be CNS-specific, as no correlation was seen in 39 patients with MS who had CSF and serum samples analyzed simultaneously ( figure 1C ).
To determine whether CSF 8-iso-PGF 2a level elevations were a secondary effect of treatment, we analyzed 31 untreated patients with MS (6 RRMS, 17 SPMS, and 8 PPMS) and 10 controls and found results comparable to our initial cohort ( figure 1D ). This analysis suggests that our findings were not a treatment-induced phenomenon. A longitudinal analysis of the repeat samples collected from 23 patients over a period of a year or more was also done. As can be seen in figure 1E , 8-iso-PGF 2a levels in the CSF of 18 individual patients were found to vary over time (p , 0.005), even though some patient samples (n 5 5) did not show any significant variation over this period of time.
CSF 8-iso-PGF 2a levels correlate with other indicators of oxidative stress. In order to establish oxidative stress, we also measured other parameters of oxidative stress/lipid peroxidation, namely MDA via TBARS, GSSG, and SOD, in the CSF samples of patients with MS. In the 124 samples assayed for all the different parameters, CSF 8-iso-PGF 2a levels showed a high correlation with TBARS (r 5 0.78) and GSSG (r 5 0.63) but did not correlate with SOD (r 5 0.016), as shown in figure 2.
Total antioxidant status of CSF is decreased in patients with MS. The antioxidant status of patients with MS was also investigated. TAS as determined by the overall nonenzymatic antioxidant capacity samples showed a decrease (p , 0.0001) in the CSF of patients with MS (n 5 231; mean 6 SD 5 121.8 6 45.3 mMol) compared to the control CSF samples (n 5 40; 258.3 6 113.3 mMol), as shown in figure 3 . The TAS was most uniformly reduced in progressive forms of MS, with the most pronounced decrease observed in the SPMS group.
These CSF results of TAS provide additional support for the occurrence of oxidative stress in MS as shown by the lipid peroxidation assays.
Neural 8-iso-PGF 2a levels are increased in an experimental model of MS and by "stressed" glial cells in culture. To determine whether 8-iso-PGF 2a levels are increased in experimental models of demyelination, we measured levels of 8-iso-PGF 2a in whole-brain lysate of mice induced with EAE and compared the values to those in the brain lysates of control mice ( figure 4A ). The EAE mice were sacrificed at disease peak (i.e., on day 15) and had a mean disability score of 7.8 6 2.1 on a 0-13 scale. 22, 23 In EAE, levels of 8-iso-PGF 2a (0.784 6 0.03 pg/mg tissue) at peak of disease (day 15) were higher (p , 0.003 value) than the levels in control mice (0.372 6 0.71 pg/mg tissue).
To determine whether 8-iso-PGF 2a is produced by glial cells under oxidative stress conditions, we investigated the glial cell line CG4 in culture. The addition of H 2 O 2 or the reactive oxygen generator AAPH to CG4 cells in culture significantly increased the 8-iso-PGF 2a levels in an assay of culture medium. Furthermore, the levels of 8-iso-PGF 2a increased in a dose-dependent manner, and the increase was inhibited by preincubation with the ROS scavenger EUK134 (figure 4B). DISCUSSION MS is a disease of unknown etiology, although there is evidence that genetic, autoimmune, and environmental factors all contribute to the pathophysiology of the disease. 25 Despite many advances in immunotherapy, complete cessation of disease activity and progression is not possible in all cases. 3 It is thus postulated that in addition to autoimmune factors, mechanisms such as oxidative stress directly or indirectly related to inflammation contribute to disease activity and progression. 3, 5 At present there is no established biomarker indicative of oxidative stress in MS, so its impact on the pathophysiology of the disease is difficult to quantify. [25] [26] [27] In this study we measured CSF isoprostane 8-iso-PGF 2a levels to determine its possible utility as a biomarker of oxidative stress in MS. Isoprostane 8-iso-PGF 2a is an established biomarker for oxidative stress and the associated lipid peroxidation in multiple human diseases including cardiovascular diseases, diabetes and obesity, cigarette smoking, and immune disorders like rheumatoid arthritis. 12, 13 Previous studies on isoprostanes in MS have reported increased levels of 8-iso-PGF 2a in urine, 14 plasma, 16 and CSF [17] [18] [19] [20] in patients with MS. However, the sample sizes were rather small, and the studies on CSF were based on early-stage MS or clinically isolated syndrome. [17] [18] [19] A later study 20 found that elevated CSF levels of 8-iso-PGF 2a did not correlate with markers of levels Figure 4 8-Iso-PGF 2a increases in vivo during EAE and during oxidative insult in cell culture (A) 8-Iso-prostaglandin F 2a (8-iso-PGF 2a ) levels in whole-brain lysate of mice induced with experimental allergic encephalomyelitis (EAE) was induced in 8-week-old mice. Mice were sacrificed at peak of disease (day 15) and whole-brain lysates were prepared. Shown here are the 8-iso-PGF 2a levels as determined by ELISA. *** indicates statistical significance with a p value of ,0.05. (B) 8-Iso-PGF 2a is produced by glial cells under oxidative stress conditions. The glial cell line CG4 was subjected to oxidative stress in culture by the addition of 50 mM hydrogen peroxide (H 2 O 2 ) or the reactive oxygen generator 2,29-azobis-2-methyl-propanimidamide dihydrochloride AAPH). Reactive oxygen species (ROS) scavenger EUK134 was added to quench the ROS released. The 8-iso-PGF 2a levels were then assayed in the cell culture medium by ELISA. The experiment is a mean of n 5 3 and *** indicates statistical significance with a p value of ,0.05. of inflammatory activity in an RRMS population (n 5 41). They suggested that 8-iso-PGF 2a may represent a sensitive marker of degenerative phenomena, independent of inflammatory activity. 20 Our study aimed to investigate 8-iso-PGF 2a levels in the CSF of patients with MS across disease stages/progression to establish lipid peroxidation and investigate it as a marker of oxidative stress in MS.
In our analysis we found that CSF levels of 8-iso-PGF 2a less than 20 pg/mL were present in all normal controls (N 5 24) and in all patients with ONDs (N 5 16). Taken as a group, patients with MS (N 5 231) had significantly elevated mean CSF 8-iso-PGF 2a levels compared to controls. However, 57% of patients with RRMS, 30% of patients with SPMS, and 35.8% of patients with PPMS had CSF values of 8-iso-PGF 2a in the "normal" range, suggesting that oxidative stress may not be a universal phenomenon in MS. Modest elevations of CSF isoprostane (20-80 pg/mL) were observed in 40% of patients with RRMS and in a greater proportion of patients with progressive disease (38.9% SPMS, 64.2% PPMS). CSF isoprostane levels higher than 100 pg/mL were only seen in a subset of patients with SPMS (31% of all SPMS samples [N 5 90]). It may be postulated from this data that oxidative stress as indicated by CSF isoprostane levels is not a universal phenomenon in all forms of MS but rather a particular manifestation of inflammatory neurodegeneration best illustrated by a subset of patients with SPMS. This occurrence is not a medication effect because it is seen in treatment-naive patients and furthermore it correlates with other markers of oxidative stress. The levels of CSF 8-iso-PGF 2a in patients with MS were significantly higher in patients with recent relapses, changes in EDSS, or recent new brain MRI lesions compared to clinically stable patients with MS, suggesting a correlation between oxidative stress and disease activity. Furthermore, the TAS as reflected in the CSF appears compromised in patients with MS compared to controls. Our CSF clinical findings were supported by experimental data in which higher 8-iso-PGF 2a levels were found in EAE brain tissue compared to normal brain. These findings suggest that oxidative stress as measured by CSF levels of 8-iso-PGF 2a is a pathophysiologic phenomenon in MS and is a potential biomarker of disease activity related to oxidative stress in progressive forms of MS.
Oxidative stress in general and isoprostanes and other lipid peroxidation products in particular may contribute to the pathogenesis of MS by a variety of mechanisms. Oxidative stress may directly lead to neuronal and axonal loss, but oxidative stress can also regulate the function of different immune cells. 28, 29 One study 30 demonstrated that oxidative stress alters B-cell function in part by increasing proteolysis within the cells. As a result, the amount of antigen presented to the specific T cells is reduced. Isoprostanes and other lipid peroxidation products can initiate signaling cascades to regulate cell viability and toxicity. 30, 31 Lipid peroxidation can also lead to changes in neurotransmission and signaling by simply altering the neuronal membrane fluidity and permeability and the stereotypic presentation of the membrane receptor. [32] [33] [34] [35] If validated by additional studies, measurement of CSF isoprostane levels may have clinical application, such as in selecting "likely responders" and in monitoring the clinical efficacy of medications purported to affect oxidative stress in MS. Thus, it would be of interest to determine whether there is a correlation between high pretreatment CSF isoprostane levels and treatment responders with agents such as dimethyl fumarate (DMF) in patients with RRMS. 35 Also, it is possible that as treatment trials in patients with progressive disease are considered, pretreatment levels of CSF 8-iso-PGF 2a may be measured to later determine whether the patients with the highest levels responded more favorably to DMF. It is probable that other disease-modifying agents that affect inflammation also affect CSF isoprostane levels. Thus if correlation of CSF isoprostane levels with therapeutic response can be shown, oxidative stress markers would have utility as biomarkers of treatment efficacy.
These preliminary findings are exciting because they show that CSF analysis may allow determination of oxidative stress in MS. Further studies are needed to confirm this work using an independent cohort and to investigate the mechanisms linking oxidative stress and disease progression.
